Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.4294
+0.0094 (2.24%)
At close: May 12, 2025, 4:00 PM
0.4295
+0.0001 (0.02%)
After-hours: May 12, 2025, 7:28 PM EDT
Cosmos Health Revenue
In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth. Cosmos Health had revenue of $14.22M in the quarter ending December 31, 2024, a decrease of -10.20%.
Revenue (ttm)
$54.43M
Revenue Growth
+1.97%
P/S Ratio
0.15
Revenue / Employee
$365,278
Employees
149
Market Cap
11.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
COSM News
- 5 days ago - Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units - GlobeNewsWire
- 6 days ago - Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq - GlobeNewsWire
- 12 days ago - Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 - GlobeNewsWire
- 26 days ago - Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million - GlobeNewsWire
- 4 weeks ago - Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L - GlobeNewsWire
- 4 weeks ago - Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order - GlobeNewsWire
- 2 months ago - Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates - Accesswire
- 2 months ago - Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 - Accesswire